New hope for Hard-to-Treat thyroid cancer: drug XL092 enters human trials
Disease control
Recruiting now
This phase 2 trial tests a drug called XL092 in 33 people with advanced thyroid cancer that has stopped responding to radioiodine therapy. XL092 works by blocking a protein that helps cancer cells grow. The study aims to see if the drug can slow or stop cancer progression.
Phase: PHASE2 • Sponsor: Jochen Lorch • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC